Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: A hellenic cooperative oncology group phase II study

Cancer Investigation

Volumn 18, Issue 6, 2000, Pages 503-509

  Fountzilas, George ^a   Nicolaides, Costas ^b   Bafaloukos, Dimitrios ^c   Kalogera Fountzila, Anna ^a   Kalofonos, Haralampos ^d   Samelis, George ^e   Aravantinos, Gerasimos ^f   Pavlidis, Nicholas ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c METAXA CANCER HOSPITAL   (Greece)

^d UNIVERSITY OF PATRAS   (Greece)

^e HIPPOKRATION HOSPITAL   (Greece)

^f AGII ANARGIRI CANCER HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; ONDANSETRON;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESISTANCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0033931583     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009012188     Document Type: Article

References (22)

1. Buzdar AV, Legha S, Hortobagyi G, et al: Management of breast cancer patients failing adjuvant chemotherapy with adriamycin containing regimens. Cancer 47:2798-2802, 1981.
2. Abbruzzese JL, Grunewald R, Weeks EA, et al: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991.
3. Anderson H, Lund B, Bach F, et al: Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12:1821-1826, 1994.
4. Gatzemeier U, Shepherd FA, Le Chevalier T, et al: Activity of gemcitabine in patients with non-small cell lung cancer: a multicenter, extended phase II study. Eur J Cancer 32a:243-248, 1996.
5. Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2,2 difluorodeoxycytidine) in patients with adenocarcinonia of the pancreas. Invest New Drugs 12:29-34, 1994.
6. Rothenberg ML, Moore MJ, Cripps MC. et al: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7:347-353, 1996.
7. Shapiro JD, Millward MJ, Rischin D, et al: Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63:89-93, 1996.
8. Stadler WM, Kuzel T, Roth B, et al: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394-3398, 1997.
9. Catimel G, Vermorken JB, Clavel M, et al: A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5:543-547, 1994.
10. Carmichael J, Possinger K, Phillip P, et al: Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13:2731-2736, 1995.
11. Bissery MC, Guenard D, Gueritte-Voegelein F, et al: Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue. Cancer Res 51:4845-4852, 1991.
12. Chevallier B, Fumoleau P, Kerbrat P, et al: Docetaxel is a major cytotoxic drug tor the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314-322, 1905.
13. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958.
14. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995.
15. Fountzilas G, Athanassiades A, Giannakakis Th, et al: A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 32A:47-51, 1996.
16. Fountzilas G, Athanassiadis A, Kalogera-Fountzila A, et al: Paclitaxel by 3-hour infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study. Eur J Cancer 33:1893-1895, 1997.
17. Ravdin PM, Burris HA III, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant oranthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995.
18. Spielmann M, Kalla S, Liombart-Cussac A, et al: Activity of gemcitabine in metastatic breast cancer patients previously treated with anthracycline-containing regimens. Eur J Cancer 33(Suppl 8): 149, 1997 (abstract).
19. Sanchez-Rovira P, Mohedano N, Moreno MA, et al: Preliminary results from an early phase II combination of gemcitabine and taxol in metastatic breast cancer. Eur J Cancer 33(Suppl 8):154, 1997 (abstract).
20. Mavroudis D, Kouroussis Ch, Malamos N, et al: A phase II trial of docetaxel and gemcitabine as second line treatment in metastatic breast cancer. Proc Am Soc Clin Oncol 17:158a, 1998 (abstract).
21. Nabholtz JM, Smylie M, Mackey J, et al: Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer. Oncology 11(Suppl 6):25-27, 1997.
22. Ten Bokkel Huinink WW, Prove AM, Piccart M, et al: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. Ann Oncol 5:527-532, 1994.